Literature DB >> 14504136

Pharmacological profile of the 5-HT-induced inhibition of cardioaccelerator sympathetic outflow in pithed rats: correlation with 5-HT1 and putative 5-ht5A/5B receptors.

Araceli Sánchez-Lopez1, David Centurión, Erika Vázquez, Udayasankar Arulmani, Pramod R Saxena, Carlos M Villalón.   

Abstract

Continuous infusions of 5-hydroxytryptamine (5-HT) inhibit the tachycardiac responses to preganglionic (C7-T1) sympathetic stimulation in pithed rats pretreated with desipramine. The present study identified the pharmacological profile of this inhibitory action of 5-HT. The inhibition induced by intravenous (i.v.) continuous infusions of 5-HT (5.6 microg x kg-1x min-1) on sympathetically induced tachycardiac responses remained unaltered after i.v. treatment with saline or the antagonists GR 127935 (5-HT1B/1D), the combination of WAY 100635 (5-HT1A) plus GR 127935, ritanserin (5-HT2), tropisetron (5-HT3/4), LY215840 (5-HT7) or a cocktail of antagonists/inhibitors consisting of yohimbine (alpha2), prazosin (alpha1), ritanserin, GR 127935, WAY 100635 and indomethacin (cyclooxygenase), but was abolished by methiothepin (5-HT1/2/6/7 and recombinant 5-ht5A/5B). These drugs, used in doses high enough to block their respective receptors/mechanisms, did not modify the sympathetically induced tachycardiac responses per se. I.v. continuous infusions of the agonists 5-carboxamidotryptamine (5-CT; 5-HT1/7 and recombinant 5-ht5A/5B), CP 93129 (r5-HT1B), sumatriptan (5-HT1B/1D), PNU-142633 (5-HT1D) and ergotamine (5-HT1B/1D and recombinant 5-ht5A/5B) mimicked the above sympatho-inhibition to 5-HT. In contrast, the agonists indorenate (5-HT1A) and LY344864 (5-ht1F) were inactive. Interestingly, 5-CT-induced cardiac sympatho-inhibition was abolished by methiothepin, the cocktail of antagonists/inhibitors, GR 127935 or the combination of SB224289 (5-HT1B) plus BRL15572 (5-HT1D), but remained unchanged when SB224289 or BRL15572 were given separately. Therefore, 5-HT-induced cardiac sympatho-inhibition, being unrelated to 5-HT2, 5-HT3, 5-HT4, 5-ht6, 5-HT7 receptors, alpha1/2-adrenoceptor or prostaglandin synthesis, seems to be primarily mediated by (i). 5-HT1 (probably 5-HT1B/1D) receptors and (ii). a novel mechanism antagonized by methiothepin that, most likely, involves putative 5-ht5A/5B receptors.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14504136      PMCID: PMC1574076          DOI: 10.1038/sj.bjp.0705489

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  55 in total

Review 1.  GR127935: a potent and selective 5-HT1D receptor antagonist.

Authors:  M Skingle; D T Beattie; D I Scopes; S J Starkey; H E Connor; W Feniuk; M B Tyers
Journal:  Behav Brain Res       Date:  1996       Impact factor: 3.332

Review 2.  Modulation of neuroeffector transmission.

Authors:  M J Rand; H Majewski; H Wong-Dusting; D F Story; R E Loiacono; J Ziogas
Journal:  J Cardiovasc Pharmacol       Date:  1987       Impact factor: 3.105

3.  5-Hydroxytryptamine inhibits the tachycardia induced by selective preganglionic sympathetic stimulation in pithed rats.

Authors:  C M Villalón; D Centurión; M del Mar Fernández; A Morán; A Sánchez-López
Journal:  Life Sci       Date:  1999       Impact factor: 5.037

4.  Characterization of prejunctional 5-HT receptors mediating inhibition of sympathetic vasopressor responses in the pithed rat.

Authors:  C M Villalón; J Contreras; E Ramírez-San Juan; C Castillo; M Perusquía; J A Terrón
Journal:  Br J Pharmacol       Date:  1995-12       Impact factor: 8.739

5.  Mediation of 5-hydroxytryptamine-induced tachycardia in the pig by the putative 5-HT4 receptor.

Authors:  C M Villalón; M O den Boer; J P Heiligers; P R Saxena
Journal:  Br J Pharmacol       Date:  1990-08       Impact factor: 8.739

6.  The pharmacological characterization of a novel selective 5-hydroxytryptamine1A receptor antagonist, NAD-299.

Authors:  L Johansson; D Sohn; S O Thorberg; D M Jackson; D Kelder; L G Larsson; L Rényi; S B Ross; C Wallsten; H Eriksson; P S Hu; E Jerning; N Mohell; A Westlind-Danielsson
Journal:  J Pharmacol Exp Ther       Date:  1997-10       Impact factor: 4.030

Review 7.  International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin).

Authors:  D Hoyer; D E Clarke; J R Fozard; P R Hartig; G R Martin; E J Mylecharane; P R Saxena; P P Humphrey
Journal:  Pharmacol Rev       Date:  1994-06       Impact factor: 25.468

8.  3H-TVX Q 7821: identification of 5-HT1 binding sites as target for a novel putative anxiolytic.

Authors:  W U Dompert; T Glaser; J Traber
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-02       Impact factor: 3.000

9.  Facilitation of 8-OHDPAT-induced forepaw treading of rats by the 5-HT2 agonist DOI.

Authors:  J Arnt; J Hyttel
Journal:  Eur J Pharmacol       Date:  1989-02-14       Impact factor: 4.432

10.  3-(1,2,5,6-Tetrahydropyrid-4-yl)pyrrolo[3,2-b]pyrid-5-one: a potent and selective serotonin (5-HT1B) agonist and rotationally restricted phenolic analogue of 5-methoxy-3-(1,2,5,6-tetrahydropyrid-4-yl)indole.

Authors:  J E Macor; C A Burkhart; J H Heym; J L Ives; L A Lebel; M E Newman; J A Nielsen; K Ryan; D W Schulz; L K Torgersen
Journal:  J Med Chem       Date:  1990-08       Impact factor: 7.446

View more
  10 in total

1.  5-Hydroxytryptamine does not reduce sympathetic nerve activity or neuroeffector function in the splanchnic circulation.

Authors:  Emma S Darios; Susan M Barman; Hakan S Orer; Shaun F Morrison; Robert P Davis; Bridget M Seitz; Robert Burnett; Stephanie W Watts
Journal:  Eur J Pharmacol       Date:  2015-02-28       Impact factor: 4.432

2.  5-HT7 receptor-mediated dilatation in the middle meningeal artery of anesthetized rats.

Authors:  José A Terrón; Esther Martínez-García
Journal:  Eur J Pharmacol       Date:  2007-01-19       Impact factor: 4.432

3.  Fluoxetine Treatment Decreases Cardiac Vagal Input and Alters the Serotonergic Modulation of the Parasympathetic Outflow in Diabetic Rats.

Authors:  Mónica García-Domingo; José Ángel García-Pedraza; Juan Francisco Fernández-González; Cristina López; María Luisa Martín; Asunción Morán
Journal:  Int J Mol Sci       Date:  2022-05-20       Impact factor: 6.208

4.  Pharmacological profile of the clonidine-induced inhibition of vasodepressor sensory outflow in pithed rats: correlation with alpha(2A/2C)-adrenoceptors.

Authors:  C M Villalón; J A Albarrán-Juárez; J Lozano-Cuenca; H H Pertz; T Görnemann; D Centurión
Journal:  Br J Pharmacol       Date:  2008-02-25       Impact factor: 8.739

5.  Further characterization of the 5-HT1 receptors mediating cardiac sympatho-inhibition in pithed rats: pharmacological correlation with the 5-HT1B and 5-HT1D subtypes.

Authors:  Araceli Sánchez-López; David Centurión; Erika Vázquez; Udayasankar Arulmani; Pramod R Saxena; Carlos M Villalón
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-12-12       Impact factor: 3.000

Review 6.  Cardiovascular responses produced by 5-hydroxytriptamine:a pharmacological update on the receptors/mechanisms involved and therapeutic implications.

Authors:  Carlos M Villalón; David Centurión
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-08-17       Impact factor: 3.000

7.  The role of dopamine D2, but not D3 or D4, receptor subtypes, in quinpirole-induced inhibition of the cardioaccelerator sympathetic outflow in pithed rats.

Authors:  A H Altamirano-Espinoza; A González-Hernández; G Manrique-Maldonado; B A Marichal-Cancino; I Ruiz-Salinas; C M Villalón
Journal:  Br J Pharmacol       Date:  2013-11       Impact factor: 8.739

8.  Pharmacological characterization of ergotamine-induced inhibition of the cardioaccelerator sympathetic outflow in pithed rats.

Authors:  Luis E Cobos-Puc; Carlos M Villalón; Araceli Sánchez-López; Martha B Ramírez-Rosas; Jair Lozano-Cuenca; Heinz H Pertz; Tilo Görnemann; David Centurión
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-09-09       Impact factor: 3.000

9.  Characterization of binding, functional activity, and contractile responses of the selective 5-HT1F receptor agonist lasmiditan.

Authors:  Eloísa Rubio-Beltrán; Alejandro Labastida-Ramírez; Kristian A Haanes; Antoon van den Bogaerdt; Ad J J C Bogers; Eric Zanelli; Laurent Meeus; A H Jan Danser; Michael R Gralinski; Peter B Senese; Kirk W Johnson; Joseph Kovalchin; Carlos M Villalón; Antoinette MaassenVanDenBrink
Journal:  Br J Pharmacol       Date:  2019-11-07       Impact factor: 8.739

10.  Role of peripheral 5-HT5A receptors in 5-HT-induced cardiac sympatho-inhibition in type 1 diabetic rats.

Authors:  José Ángel García-Pedraza; Oswaldo Hernández-Abreu; Asunción Morán; José Carretero; Mónica García-Domingo; Carlos M Villalón
Journal:  Sci Rep       Date:  2020-11-09       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.